

Environmental Political Engagement Report

Our environmental, social, and governance, or ESG, strategy begins with our mission to serve patients by developing, manufacturing and delivering drugs that treat serious illnesses. In the course of that work, we also support our employees and their families, we contribute to the well-being of our local communities, and we operate our business in an ethical, environmentally responsible, and socially inclusive manner. In connection with our regular engagement with our stakeholders, we were requested to provide specific information about our environmental political engagement and the discussion below is in response to this request. More detail on our ESG strategy generally can be found at Amgen.com in our "Responsibility" section located here and our "How We Operate" section located <a href=here.

Responsible Oversight and Governance of Environmental Sustainability and Political Engagement by Our Board, its Committees, and Our Executives

Our Board, its committees, and our executives oversee our ESG strategy and our political engagement. The Corporate Responsibility and Compliance Committee ("CRCC") of the Board of Directors oversees our environmental sustainability strategy and activities and our government affairs activities, including our political contributions, public policy positions with respect to pending legislative or other initiatives, as well as the processes by which we make charitable contributions (including the activities of The Amgen Foundation and the Amgen Safety Net Foundation ¹). The Board's Audit Committee provides oversight of our disclosure processes in support of our ESG reporting, as well as oversight of assurance of key data in our ESG Report, including progress against our environmental targets. The CRCC and Audit Committee are each composed of independent outside directors and provide regular updates to the Board of Directors. Our executive management provides regular updates to the Board and its committees regarding the status and progress of the Company's ESG activities, including environmental sustainability updates.

Our Senior Vice President, Corporate Affairs leads the Company's ESG efforts. Our cross-functional executive-level ESG Council, chaired by the Senior Vice President, Corporate Affairs, sets and reviews the Company's environmental sustainability strategy and programs, provides guidance on program implementation, and oversees the continuing enhancement of our approach to ESG. The Council regularly evaluates current and emerging ESG-related risk topics that are relevant to our business.

Our ESG framework is built on four strategic pillars discussed below. "Healthy planet," a key strategic pillar, focuses on our prioritization of sustainability and aim to minimize our environmental impact. Initiative steering committees ("ISC"s), each aligned with one of the four strategic pillars, support the ESG Council. Each ISC coordinates the implementation of the strategy for its respective pillar and integrates our ESG strategy into the Company with the support of subject-matter-expert working teams. ISC members identify emerging ESG issues that could impact our business, employees, communities or stakeholders and, when appropriate, raise them with the ESG Council for discussion and analysis.

Our Senior Vice President, Global Government Affairs and Policy leads the Global Government Affairs and Policy ("GGA&P") team with the oversight by the CRCC. Our GGA&P team participates responsibly and constructively in the legislative process by educating elected officials and other policymakers in Washington, D.C., and in state capitols around the U.S. about public policies that are consistent with our mission to serve patients. We are committed to complying with all applicable laws, rules, and regulations that govern our political engagements. Lobbying is highly regulated in the U.S. through a variety of state and federal registration and reporting laws. We require that our employees and outside firms comply with the Lobbying Disclosure Act and Honest Leadership and Open Government Act.

This report focuses on our approaches to behaving in an environmentally responsible manner, including with respect to our political engagement.

¹ The Amgen Foundation, Inc. and the Amgen Safety Net Foundation are separate legal entities funded entirely by Amgen.

Our Forms of and Approaches to Environmentally Responsible Political Engagement

Trade and Industry Associations

We maintain memberships in trade and industry associations that champion scientific innovation and patient access to new and existing therapies and whose missions align with Amgen's business and policy interests. Our participation in trade and industry associations can offer significant benefits by providing access to policy and government affairs expertise, business, technical and industry benchmarking data and standard-setting expertise, and by advancing our business interests.

Considerations We Use in Evaluating Potential Political Contributions and Potential Memberships in Trade or Industry Associations

We evaluate our political contributions and memberships in trade or industry associations regularly and contributions are guided by our mission to serve patients. We are steered by our values, accessible here, and our Code of Conduct, accessible here, and our Code of Conduct, accessible here.

In addition to positions on health care policy issues, we recognize that candidates and trade or industry associations may engage in a broad range of other issues that extend beyond the scope of what is of primary importance to us in our mission to serve patients. Before joining a trade or industry association, our GGA&P team reviews the proposed membership to ensure it aligns with Amgen's mission and business interests. We also regularly re-evaluate our memberships in trade and industry associations to determine that they continue to serve the long-term interests of our Company, stockholders, employees, and communities, and that the overall benefit of memberships in these associations outweighs differences that from time to time arise. Given the wide range of issues addressed by these associations, our positions will not always align entirely with those of the trade or industry associations to which we belong. We advise the trade or industry associations in which we participate of our views on certain broader public policies or regulatory issues.

Lobbying

While we do not directly lobby for climate change, we believe we demonstrate our capacity to contribute to addressing the challenges of climate change and, in turn, seek to influence public policy decisions of lawmakers and regulators by setting, communicating, and delivering on ambitious environmental goals (discussed in depth under "Our Commitment to the Environment" below) that demonstrate what can be achieved.

Lobbying Activity Transparency

We are transparent about our lobbying activities. At the federal level, we file a quarterly report that lists the issues on which we have conducted federal lobbying activities with the Office of the Clerk of the U.S. House of Representatives and the Secretary of the U.S. Senate. These quarterly lobbying activity reports are available in the House or Senate databases. Additionally, we expect any third parties with which we are affiliated and that engage in federal lobbying activities to report these activities. Annually, we post a list of states where we file lobbying reports and, to the extent available, either links to the reports filed with each state or links to state websites where such information can be found. Our most current report of such state lobbying information can be found here.

Results of Our Annual Review of U.S. Trade and Industry Associations That Conduct Climate Lobbying and Alignment on Climate Lobbying

Environmental sustainability is important to us and, in 2023, we reviewed and analyzed our U.S. trade association memberships with an emphasis on the climate-focused lobbying activities by associations in which Amgen² is a member. As noted below, we disclose payments to certain U.S. trade associations, and the specific amounts identified by such trade associations as being used for lobbying expenditures ("Lobbying Support"), here. While Amgen is not providing direct Lobbying Support, we are members of trade associations that align with business interests and policy goals. Our process and methodology included reviewing our memberships and conducting an assessment of climate-related policy and advocacy positions to determine alignment with the Paris Agreement's goal of limiting the global average temperature rise to 1.5 degrees Celsius.

We did not identify any areas of climate-related policy or Paris Agreement misalignment with any such U.S. trade associations. If misalignment with U.S. trade and industry associations in which Amgen is a member is identified in the future, we will consider

² Horizon Therapeutics plc was excluded from our 2023 review given the October 2023 timing of this acquisition.

whether or not to remain a member. We may see a broader value in certain of our memberships, for example sharing of industry best practices. We will continue to closely monitor these associations.

For those U.S. trade and industry associations in which Amgen is a member and conduct climate lobbying, no Amgen executive officer has a leadership role (such as serving on the board or a relevant committee of the board of such entities).

Engagement With Non-Profit, Social Welfare, and Related Organizations

We are members of the Renewable Thermal Collaborative ("RTC"). The RTC is a global coalition for companies, institutions, and governments committed to scaling up renewable heating and cooling at their facilities, dramatically cutting carbon emissions. RTC members recognize the growing demand and necessity for renewable heating and cooling and the urgent need to meet this demand in a manner that delivers sustainable, cost-competitive options at scale. The goal of the RTC is to create a community of corporate buyers, establish policy support and establish a path of decarbonization. A sub-group within the RTC evaluates policy.

We have participated in the Environmental Defense Fund ("EDF") Climate Corp Fellows program to assist us in accelerating our climate and clean energy efforts. EDF fellows have also published public papers³ as a collaborative work with Amgen. We continue to monitor the EDF's activities and plan to provide further support as opportunities are identified. Additionally, we have been a long-standing member of the Clean Energy Buyers Association, which began as a collaboration with BSR (formerly, the Business for Social Responsibility), Rocky Mountain Institute, the World Resources Institute, and the World Wildlife Fund. We are pleased to report that such participation was an outgrowth of our previous engagements with certain of our stakeholders.

We are a member of the American Enterprise Institute ("AEI"), a 501(c)(3) organization; however, we engage with AEI's healthcare scholars (and not their environmental scholars) and, as such, we have not signed on to AEI's climate policy advocacy activities. We do not believe that we have any significant activity to report with respect to our use of 501(c)(4) organizations.

Other Resources

Please see our key environmental efforts as showcased on our <u>website</u>, our annual environmental, social, and governance report and via our <u>LinkedIn</u>, <u>Instagram</u>, and <u>Twitter</u> postings.

Our ESG Integration Activities

In 2021, 2022, and 2023 to further integrate ESG across the organization, we added ESG targets to our Company-wide performance goals within our annual incentive compensation plan.



Our Commitment to the Environment

Our engagement is also manifested in the activities that we undertake in support of our values, including our activities in support of the environment that are part of our ESG efforts such as:

Carbon Neutrality. As a science-based company committed to advancing human health, we recognize the impact
that climate change is having on human health around the world. We have a long-standing objective to conduct
environmentally responsible operations and regularly set targets to challenge ourselves to deliver further

For example, please see http://edfclimatecorps.org/sites/edfclimatecorps.org/files/amgen_onepager_1-8.pdf? ga*OTQxMjE2MzgwLjE2NDM3MzM2MTA.*ga WE3BPRQKW0*MTY0MzczMzYwOS4xLjEuMTY0MzczMzYxMi41N w.

improvements. Since 2007, we have successfully advanced our environmental sustainability program while substantially increasing our global production capacity. Building on the successful execution of our 2013-2020 conservation targets, we launched a new environmental sustainability plan in 2021 (our third since 2007) that includes a target of achieving carbon neutrality in our owned and operated facilities by 2027, while also aiming to further reduce our water use (by 40%) and waste disposal (by 75%).⁴

To achieve our 2027 environmental plan goals, we plan to harness our innovative capabilities to work to combat climate change and preserve natural resources. Our 2027 environmental plan is designed to drive specific environmental sustainability projects across our operations, including continued investment in our smaller footprint, highly-resource efficient biomanufacturing, smart and integrated facility design, use of on-site solar and other renewable energy sources, electric vehicle fleet conversion, treatment and reuse of water, the reduction and recycling of single-use plastics, and the reduction of consumables packaging.

Our target to achieving carbon neutrality in our owned and operated facilities by 2027 is designed to lead by example in our support of activities contributing to society's progress towards the Paris Agreement's goal of limiting the global average temperature rise to 1.5 degrees Celsius. A description of our recent climate activities in support of our 2027 environmental sustainability plan goals include our three-pronged approach designed to combat climate change with internal and external innovation that focuses on:

- 1) Innovation: Reducing the amount of energy (carbon) required to develop and produce our medicines.
- 2) <u>Efficiency</u>: Embedding sustainability-by-design into our facilities to maximize their operational efficiency.
- 3) Renewable Energy: The generation and procurement of clean, renewable energy is an important component of achieving our 2027 carbon neutrality target.⁵ Our aim is for all of our facilities, wherever feasible, to procure 100% renewable electricity by 2027.
- Manufacturing Facilities. Through innovative manufacturing technologies implemented at our manufacturing facility in Singapore, we reduced carbon emissions by 69% and water use by 54%, as compared to conventional biotechnology manufacturing.⁶ In January 2022, we received FDA approval for a new manufacturing facility in Rhode Island utilizing the same technologies as our facility in Singapore. In addition, we are embedding environmental sustainability into upfront project design, development, and execution at two new facilities in Ohio and North Carolina. For example, at our new multiproduct drug substance manufacturing facility in North Carolina, we expect our carbon footprint and water usage to be substantially lower than at a traditional drug substance manufacturing plant due to deployment of innovative technologies and resource conservation. In Ohio, we are building our new final product advanced assembly and packaging plant to LEED⁷ standards to maximize energy efficiency and waste reduction.
- Sustainable Value Chain. Our Supplier Sustainability Program aims to help ensure that suppliers address not only
 quality, cost, and reliability requirements, but also ethical, environmental, and social considerations, including
 business ethics, labor, human rights, and environmental impact. Our <u>Supplier Code of Conduct</u> sets our fundamental
 expectations of our suppliers and is aligned with our core values.
- United Nations Global Compact. We are a signatory to the United Nations Global Compact, a voluntary initiative
 based on commitments to implement universal sustainability principles and take steps to support the United Nations
 Sustainable Development Goals.

Carbon neutrality goal refers to Scope 1 and 2 emissions. Reductions take into account only verified reduction projections, do not take into account changes associated with the contraction or expansion of the Company and are measured against a 2019 baseline.

⁵ Carbon neutrality goal refers to Scope 1 and 2 emissions.

⁶ As of September 30, 2021.

⁷ Developed by the U.S. Green Building Council, LEED is a set of rating systems for the design, construction, operation, and maintenance of green buildings, homes and neighborhoods.